Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Therapeutic Advances in Medical Oncology Année : 2020

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors

(1) , (2) , (3) , , , (4) , , (5) , (6) , (7) , (8)
1
2
3
4
5
6
7
8

Résumé

Metastatic pancreatic ductal adenocarcinomas (PDACs) are now more effectively controlled using chemotherapy combinations such as FOLFIRINOX and gemcitabine plus nab-paclitaxel (NabP) regimens with a subset of patients who achieve a sustained tumor stabilization or response. The next challenge is to design maintenance therapies that result in continued tumor control with minimal toxicity. Quality of life should always be a priority in these patients with prolonged survival. Gradually tapering off the intensity of chemotherapy by suppressing drug(s) in the combination is one option. Thus, maintenance with 5-fluorouracil or gemcitabine as single agents after FOLFIRINOX or gemcitabine-NabP induction, respectively, seems to be a promising approach to minimize neurotoxicity while maintaining efficacy. Another option is to introduce maintenance drug(s) with different anti-tumoral actions. The recent example of olaparib in patients with BRCA mutated PDAC provides a promising proof-of-concept of a switch maintenance strategy in this setting.

Dates et versions

hal-03285853 , version 1 (13-07-2021)

Identifiants

Citer

Pascal Hammel, Carole Vitellius, Émeric Boisteau, Mathilde Wisniewski, Elise Colle, et al.. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Therapeutic Advances in Medical Oncology, 2020, 12, pp.175883592093794. ⟨10.1177/1758835920937949⟩. ⟨hal-03285853⟩
25 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More